Safeguarding Circulating Tumor DNA Testing in Viet Nam: Appropriate Use, Result Limitations and Confirmatory Pathways
DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT
11/6/202627 min read


Safeguarding Circulating Tumor DNA Testing in Viet Nam: Appropriate Use, Result Limitations and Confirmatory Pathways
A patient with advanced lung cancer undergoes a blood test to identify genetic alterations that could help guide treatment. The report states that no actionable alterations were detected. For the patient and clinical team, this may suggest that the tumor does not carry a mutation relevant to targeted therapy.
But the result may not tell the whole story.
Some tumors release very little DNA into the bloodstream. A clinically important alteration may be present at a concentration below the assay's detection limit, or it may belong to a class of genetic changes that the test cannot reliably identify. A negative plasma result can therefore leave an important molecular question unresolved.
The opposite problem can occur when an alteration is detected. A positive finding may support treatment selection, but not every genetic variant identified in plasma necessarily originates from the cancer. Some may arise from blood-forming cells rather than the tumor itself.
These situations illustrate why circulating tumor DNA (ctDNA) testing requires more than sophisticated molecular technology. Its reliability depends on selecting an appropriate examination, understanding what the assay can detect, interpreting findings within their limitations and determining when additional evidence is needed.
Liquid biopsy has become an important component of precision oncology, particularly when tumor tissue is difficult to obtain or timely molecular information could influence treatment. However, increasing test availability also creates opportunities for findings to be interpreted with greater certainty than the evidence supports.
In June 2026, the American Society of Clinical Oncology (ASCO) published its guideline, Circulating Tumor DNA Testing in Solid Tumors and Lymphoma. The guideline emphasizes appropriate clinical use, the limitations of plasma testing and the importance of seeking tissue-based confirmation when results are negative, inconclusive or inconsistent with the clinical circumstances.
The evidence has also advanced in molecular residual disease testing. In May 2026, the United States Food and Drug Administration (FDA) approved a specific ctDNA-guided adjuvant treatment pathway for selected patients with muscle-invasive bladder cancer. This development demonstrates that ctDNA testing can have established clinical utility in defined circumstances, while underscoring why evidence from one indication cannot automatically be extended to other cancers.
For healthcare organizations in Viet Nam, the challenge is to translate these developments into reliable diagnostic services. The priority is not simply whether ctDNA testing can be offered, but whether each examination is appropriate, analytically reliable and connected to a clinical pathway capable of resolving uncertainty.
Understanding What ctDNA Testing Can and Cannot Establish
Circulating tumor DNA consists of DNA fragments released from cancer cells into body fluids, particularly the bloodstream. These fragments form part of the broader pool of circulating cell-free DNA (cfDNA), much of which originates from nonmalignant cells.
The amount of tumor-derived DNA present in a blood sample can vary considerably between patients and clinical circumstances. This creates both opportunities and limitations for molecular diagnosis.
Depending on the technology and intended use, ctDNA assays may detect selected single-nucleotide variants, insertions, deletions, copy number alterations, gene rearrangements or other tumor-associated molecular characteristics.
Some assays use broad molecular profiling panels to identify genetic alterations relevant to treatment selection. Others detect specific resistance mutations or track previously identified tumor-associated variants over time. Personalized approaches may also be used to detect small amounts of residual cancer-associated DNA after treatment.
These are different diagnostic applications and should not be treated as interchangeable.
A test developed to identify actionable alterations in advanced cancer is not automatically suitable for detecting molecular residual disease after surgery. Similarly, an assay designed to monitor a limited number of tumor-specific variants should not be assumed to provide comprehensive genomic profiling.
Analytical sensitivity, genomic coverage, detection thresholds and clinical validation may differ substantially between assays, even when they are marketed under the same general description of liquid biopsy.
This distinction matters because a technically valid result may still be insufficient for the question the clinician needs to answer.
For example, a negative result from a panel that does not assess a particular alteration cannot establish that the alteration is absent. An assay with limited sensitivity for gene fusions may also be inadequate when detecting a fusion is essential for treatment selection.
The term liquid biopsy requires similar care. It encompasses different technologies that examine tumor-associated material in body fluids. Not every liquid biopsy method measures ctDNA, and not every ctDNA assay has the same clinical purpose.
Reliable implementation begins by establishing what the examination measures, which clinical question it is intended to address and what evidence supports its use in that setting.
Appropriate Use Begins With a Clinical Decision
The availability of an advanced molecular test does not, by itself, justify ordering it.
The 2026 ASCO guideline recommends that, outside clinical trials, ctDNA testing should generally be offered when the findings could be applied to clinical decision-making. Testing to determine eligibility for participation in a clinical trial is also considered reasonable.
This principle is particularly important in precision oncology, where molecular testing may generate extensive technical information without necessarily identifying a clinically actionable result.
ASCO recognizes circumstances in which ctDNA testing for tumor genetic alterations may be used as an initial assessment, an alternative to tissue-based testing or an additional investigation.
These include situations in which tissue testing is challenging or infeasible, another biopsy would present unacceptable risks, tissue results cannot be obtained within a clinically useful timeframe, or an approved treatment indication permits or requires a ctDNA-based result.
The recommendation is conditional and depends on the patient's cancer type, disease stage, available tissue, treatment options and clinical circumstances.
For example, plasma-based molecular profiling may help identify actionable alterations in selected patients with advanced cancer when obtaining adequate tumor tissue is difficult or would delay an important treatment decision.
However, this does not establish that blood-based molecular profiling is preferable to tissue examination in every case.
Tumor tissue remains essential for many aspects of cancer diagnosis, including histopathological classification and investigations that cannot be adequately performed using circulating DNA alone.
The relationship between tissue and plasma testing also depends on the particular biomarker being investigated.
A clinically meaningful test request should therefore include relevant information about the patient's diagnosis, disease stage, previous molecular findings, treatment history and the decision that may depend on the result.
When the laboratory understands the intended clinical purpose, it is better positioned to determine whether the requested assay is suitable or whether another method or specimen would provide more useful evidence.
An appropriate-use policy should support these decisions rather than simply restrict access to advanced technology.
The objective is to ensure that molecular investigations address meaningful clinical questions while avoiding testing that is unlikely to contribute to patient care.
Why a Negative Plasma Result May Leave an Important Question Unanswered
One of the most consequential limitations of ctDNA testing is the possibility of false-negative results.
The amount of tumor-derived DNA circulating in plasma varies according to several biological and clinical factors. Tumor type, disease burden, anatomical location, biological characteristics and treatment exposure may all influence how much ctDNA is available for detection.
Some tumors release relatively little detectable DNA into peripheral blood. This may be particularly relevant when disease burden is low or when the anatomical location of a tumor limits the amount of tumor-derived DNA reaching the bloodstream.
Consequently, a patient may have a tumor containing an actionable genetic alteration even though that alteration is not detected in plasma.
Analytical sensitivity creates another limitation.
Every ctDNA assay has defined performance characteristics, including detection limits that depend on assay design, variant type, specimen quality and the analytical process.
An alteration present below the validated detection limit may not be identified reliably. The ability to detect one type of genetic change also does not guarantee equivalent performance for another.
The European Society for Medical Oncology (ESMO), in its 2022 recommendations on ctDNA testing, highlighted the limitations of plasma-based assays for certain structural alterations, including gene fusions and copy number changes.
These limitations remain important when treatment selection depends on identifying such findings.
A further distinction must be made between an analytically valid result in which no relevant alteration was detected and a technically unsuccessful examination.
A valid not detected result means that the assay did not identify the targeted alterations under its specified analytical conditions and detection limits. It does not necessarily establish that the tumor lacks those alterations.
An invalid, failed or inconclusive result indicates that the examination did not meet the laboratory's criteria for producing a sufficiently informative interpretation.
Neither situation should automatically be regarded as proof that the patient's cancer has no clinically relevant molecular alterations.
ESMO's recommendations emphasize the importance of communicating whether a plasma result is genuinely informative or whether insufficient tumor-derived DNA may have limited the examination.
The 2026 ASCO guideline recommends seeking tissue-based confirmation when ctDNA results are negative, inconclusive or inconsistent with the clinical scenario.
This recommendation should be applied according to the circumstances.
It does not mean that every negative plasma result requires a new invasive biopsy. If suitable tumor tissue is already available, testing that material may be appropriate. In other cases, the risks and feasibility of obtaining additional tissue must be considered.
The decision depends on the unresolved molecular question, whether further testing can reasonably be performed and whether the additional information could influence patient care.
A reliable diagnostic pathway should make these distinctions explicit so that negative plasma findings do not create inappropriate reassurance or prematurely close a clinically important investigation.
Positive Results Also Require Careful Interpretation
A positive ctDNA result may identify a genetic alteration that supports treatment selection, particularly when the finding corresponds to an established therapeutic biomarker.
Nevertheless, detecting a variant in plasma does not automatically prove that it originated from the cancer.
One important source of potentially misleading findings is clonal hematopoiesis.
Clonal hematopoiesis occurs when blood-forming cells acquire somatic mutations and a population of those cells expands over time. DNA released from these cells may enter the circulation and become detectable through plasma molecular testing.
Some genes associated with clonal hematopoiesis overlap with genes examined by oncology sequencing panels.
Without appropriate interpretation, a hematopoietic variant may be mistaken for a tumor-derived alteration.
This creates the possibility of assigning an incorrect molecular profile to the cancer or considering treatment based on a finding that did not originate from the tumor.
The significance of this risk depends on the gene, specific variant, cancer type, assay characteristics and clinical context.
It would be incorrect to assume that every low-frequency plasma variant represents clonal hematopoiesis. It would be equally inappropriate to assume that every detected alteration is tumor-derived.
In selected circumstances, sequencing matched white blood cell DNA can help identify variants more likely to originate from hematopoietic cells. Comparison with available tumor tissue may provide additional evidence.
These approaches have limitations and are not necessarily required for every positive result. Their use should reflect the potential consequences of an incorrect interpretation and the laboratory's validated procedures.
Another consideration is the possibility that a detected variant may be germline rather than tumor-specific.
When a plasma finding raises a credible concern about inherited cancer susceptibility, an appropriate clinical genetics evaluation may be warranted.
A suspected germline alteration should not be treated as confirmed solely on the basis of a tumor-focused plasma assay. Confirmatory genetic testing and professional assessment may be necessary according to the circumstances.
Such evaluations should be distinguished from the interpretation of somatic tumor alterations and conducted within the relevant professional, consent and confidentiality requirements.
The essential safeguard is to establish the likely biological origin and clinical relevance of a detected variant before relying on it for a consequential clinical decision.
Analytical Reliability Begins Before Molecular Analysis
CtDNA testing involves several technically demanding processes, each of which can influence the final result.
Blood collection, specimen transport, plasma separation, DNA extraction, molecular analysis, bioinformatic processing and reporting all contribute to analytical reliability.
Because tumor-derived DNA may be present at very low concentrations, relatively small technical variations can affect whether an alteration is detected.
For example, delayed processing under unsuitable conditions may allow blood cells to release additional genomic DNA. This can increase the background concentration of non-tumor DNA and make low-frequency tumor-derived signals more difficult to detect.
Collection tubes designed to stabilize cell-free DNA may permit longer transport intervals, but their performance depends on validated handling conditions and manufacturer instructions.
A specimen collection procedure validated for one testing platform should not automatically be assumed suitable for another.
During molecular analysis, laboratories need to distinguish genuine low-frequency variants from sequencing artifacts and other sources of analytical noise.
Depending on the technology, molecular error correction, adequate sequencing depth, validated bioinformatic pipelines and appropriate quality controls can improve the reliability of variant detection.
However, technical sophistication should not be confused with demonstrated analytical performance.
A test using next-generation sequencing may still have important limitations in sensitivity, specificity, genomic coverage or clinical applicability.
In May 2026, Harlé and colleagues published a French Delphi consensus on the technical standardization of ctDNA analysis in the European Journal of Cancer.
The initiative involved 39 high-volume molecular platforms and established 37 recommendations covering preanalytical, analytical, bioinformatic and postanalytical processes.
The recommendations addressed molecular error correction, plasma preparation, quality controls, evaluation of clonal hematopoiesis, reporting of variant allele frequencies and communication of assay limitations.
The consensus provides a useful technical reference for improving consistency across laboratories. However, it represents professional recommendations developed within a particular technical and regulatory context and should not be interpreted as establishing universal legal requirements.
The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium also contributed important guidance in 2026.
In January, BLOODPAC published consensus recommendations for the analytical validation of tumor-informed ctDNA assays used to detect molecular residual disease.
These protocols address the challenges of detecting very low concentrations of tumor-derived DNA and provide a foundation that test developers can adapt to their technologies and intended applications.
In May 2026, BLOODPAC published version 2.0 of its generic analytical validation protocols for next-generation sequencing-based ctDNA assays.
The May publication updated its earlier framework for assays intended to support treatment decisions in advanced solid tumors. It addressed analytical performance characteristics including detection limits, accuracy, precision, interference and specimen stability.
Its scope should not be extended automatically to early-stage MRD assays, cancer screening or multicancer early-detection testing.
The two BLOODPAC publications therefore have distinct intended uses. The January recommendations focus on tumor-informed MRD assays, while the May update refines analytical validation protocols primarily relevant to NGS-based ctDNA testing for treatment selection in advanced disease.
These documents support stronger analytical validation, but they do not establish clinical utility for every application of ctDNA testing.
For healthcare organizations, this distinction is fundamental.
An assay can perform reliably according to its validated analytical specifications without necessarily providing information that improves a particular clinical decision.
Molecular Residual Disease: Clinical Validity and Clinical Utility Are Different
One of the most rapidly developing applications of ctDNA is molecular residual disease (MRD) testing.
After treatment intended to eliminate cancer, a patient may have no visible evidence of disease on conventional imaging while small amounts of tumor-derived DNA remain detectable in blood.
In several cancers, post-treatment ctDNA positivity has been associated with an increased risk of subsequent recurrence.
This provides evidence of clinical validity: the molecular finding may help identify patients at greater risk of future disease.
However, clinical validity does not automatically establish clinical utility.
Clinical utility requires evidence that using the test result to guide management produces a meaningful benefit.
For example, identifying a patient at increased risk of recurrence does not necessarily mean that beginning additional treatment earlier will improve survival.
Treatment initiated solely because of an inadequately supported molecular finding may expose patients to toxicity, financial costs or unnecessary interventions without demonstrated benefit.
ESMO's 2022 recommendations recognized the prognostic potential of ctDNA-based MRD testing but concluded that routine use to direct treatment was not generally justified by the evidence available at that time.
The 2026 ASCO guideline similarly emphasizes the need for an evidence-supported clinical action rather than assuming that a positive MRD result should always lead to additional treatment.
These recommendations must be interpreted in the context of evolving evidence. Clinical trial findings and regulatory decisions may establish clinical utility for specific indications without supporting routine use across every cancer type.
An important example emerged in muscle-invasive bladder cancer.
IMvigor011 and the 2026 FDA Approval: A Defined Clinical Application
The phase III IMvigor011 trial evaluated ctDNA-guided adjuvant treatment after radical cystectomy in patients with muscle-invasive bladder cancer.
Patients without radiographic evidence of disease underwent serial ctDNA testing after surgery. Those meeting the trial's eligibility criteria and becoming ctDNA-positive were randomly assigned to receive atezolizumab or placebo.
The trial enrolled 761 patients, of whom 250 eligible ctDNA-positive patients underwent randomization. Of these, 167 were assigned to atezolizumab and 83 to placebo.
Median disease-free survival was 9.9 months in the atezolizumab group compared with 4.8 months in the placebo group.
Median overall survival was 32.8 months and 21.1 months, respectively.
The trial demonstrated statistically significant improvements in both outcomes within the selected ctDNA-positive population.
These findings provide randomized clinical evidence that treating patients selected through a defined ctDNA-MRD pathway can improve outcomes in this particular setting.
However, the distinction between the enrolled population and the randomized population matters.
The treatment benefit was demonstrated among eligible patients with detectable ctDNA MRD, not across all patients who underwent postoperative monitoring.
Patients who remained ctDNA-negative were not randomized to alternative treatment strategies. Their outcomes should therefore not be interpreted as proving that withholding otherwise indicated adjuvant treatment is safe for all ctDNA-negative patients.
On May 15, 2026, the FDA approved atezolizumab and atezolizumab–hyaluronidase-tqjs as adjuvant treatments for adults with muscle-invasive bladder cancer after cystectomy who have ctDNA-detected MRD, as determined by an FDA-authorized test.
The FDA also approved Signatera CDx as a companion diagnostic for this indication.
Signatera CDx is a tumor-informed assay that uses molecular information from the patient's tumor tissue to develop personalized testing for ctDNA in plasma.
Its use in this setting should not be confused with a tissue-independent plasma genotyping test.
The approval concerns a defined cancer type, patient population, diagnostic pathway and treatment indication.
It does not mean that all ctDNA-MRD assays are interchangeable or that a positive result from any assay should automatically lead to atezolizumab treatment.
Nor does it establish that every ctDNA-positive patient with another type of cancer should receive additional treatment.
The FDA decision also does not automatically establish equivalent regulatory approval, clinical availability or reimbursement arrangements in Viet Nam.
For healthcare organizations, IMvigor011 illustrates why the appropriate unit of evaluation is the complete clinical pathway: the assay, its intended use, the eligible patient population and the treatment decision supported by evidence.
Surveillance and Early Detection Require Separate Evidence
CtDNA is also being investigated for monitoring disease recurrence and detecting cancer-related molecular signals before abnormalities become apparent through conventional assessment.
These applications are promising because molecular findings may sometimes precede clinically detectable disease.
However, earlier detection does not automatically demonstrate improved outcomes.
A ctDNA result may become positive before imaging identifies recurrence, yet it may remain uncertain whether acting at that earlier point improves survival or reduces morbidity.
A negative result can also create false reassurance.
A patient may have clinically significant residual or recurrent disease despite undetectable ctDNA. Reducing or discontinuing indicated follow-up solely because of a negative result could delay recognition of recurrence.
Positive findings present different challenges.
A patient may have detectable ctDNA without an identifiable site of disease. Additional investigations, uncertainty and anxiety may follow, particularly when no evidence-supported intervention is available.
The 2026 ASCO guideline does not establish a general recommendation to replace standard surveillance methods with ctDNA testing.
Additional uses may be considered when a specific evidence-based action is available or when the result could help resolve ambiguity in standard clinical assessment.
This distinction matters because evidence varies considerably across cancer types, stages and treatment settings.
Blood-based multicancer early-detection testing represents another developing field.
Some assays examine ctDNA-associated alterations, methylation patterns or other circulating molecular characteristics to identify signals suggestive of malignancy.
However, these tests are not interchangeable with assays developed for tumor genotyping or MRD monitoring.
For asymptomatic individuals, clinical utility requires evidence concerning diagnostic accuracy, downstream investigations, patient outcomes and potential harms.
A blood-based early-detection test should not automatically be presented as a replacement for established evidence-based cancer screening programs.
The responsible approach is to match the level of clinical confidence to the evidence supporting each particular application.
Confirmatory Pathways Should Be Planned Before Testing
A ctDNA service needs more than a reliable laboratory assay. It also needs a clear process for managing results that do not adequately answer the clinical question.
This becomes particularly important when findings are negative, inconclusive, unexpected or inconsistent with other available evidence.
The response should not depend entirely on an individual clinician recognizing every technical limitation after the report has been issued.
Before testing, the clinical team should understand what result would support the intended decision and what additional assessment may be needed if the examination is uninformative.
For example, when plasma profiling is performed because tumor tissue is temporarily unavailable, the team should consider whether existing tissue can subsequently be analyzed if the plasma result does not identify relevant biomarkers.
When a detected variant may originate from clonal hematopoiesis, appropriate molecular pathology review and supplementary evidence may be necessary before using the finding for treatment selection.
When a result raises concern about a possible germline pathogenic variant, the patient may require a separate clinical genetics assessment.
MRD testing presents another situation. The appropriate response to a positive or negative finding depends on the cancer type, treatment stage, assay and evidence supporting the clinical action under consideration.
These situations should not be managed through a single rule requiring repeat testing in every case.
Tissue-based confirmation is particularly relevant when a molecular question remains unanswered and suitable tissue can be obtained or is already available.
However, certain well-supported positive plasma findings may be actionable without additional tissue-based molecular confirmation when the relevant clinical and regulatory conditions are satisfied.
The purpose of a confirmatory pathway is not to repeat every examination automatically. It is to resolve uncertainty that could materially influence patient care.
A practical pathway should identify who reviews the result, which additional evidence may be required, who arranges further investigation and how the final interpretation is incorporated into the clinical record.
Without these arrangements, the benefit of obtaining rapid molecular information may be lost through delayed follow-up or unresolved questions after the initial test.
Reporting Must Communicate the Limits of the Evidence
A reliable ctDNA report should provide more than a list of detected genetic alterations.
The receiving clinician needs to understand what was examined, which findings were identified, what the assay could not reliably assess and how the results relate to the intended clinical question.
Depending on the technology and purpose, relevant information may include specimen type, analytical methodology, genomic regions or alterations assessed, appropriate quality indicators, detection limits and the interpretation of reported findings.
Variant allele frequency may also be included.
This describes the proportion of relevant sequencing observations containing a particular alteration in the analyzed material. It should not automatically be interpreted as the percentage of cancer cells in the body or as a direct measure of overall tumor burden.
The 2026 ASCO guideline advises against using fractional, percentage-based or concentration-based measures of ctDNA or total cfDNA as surrogate measures of disease burden when the necessary clinical evidence is lacking.
This distinction matters because numerical trends can appear compelling even when their clinical meaning remains uncertain.
A decrease in measured ctDNA may be biologically interesting, but its interpretation depends on the assay, treatment setting and evidence supporting that particular use.
Negative results require equally careful reporting.
The laboratory should communicate relevant limitations involving genomic coverage, analytical sensitivity and classes of alterations that may not be detected reliably.
Where the assay cannot determine whether sufficient tumor-derived DNA was present, the report should avoid language implying that the tumor definitively lacks the alterations being investigated.
When clonal hematopoiesis is a credible explanation for a detected variant, this possibility should be considered and communicated as appropriate.
A technically unsuccessful or inconclusive examination should not be described as normal simply because no actionable alteration was identified.
The report should support professional interpretation rather than replace it with unsupported certainty.
Evidence From Viet Nam: Clinical Promise and Remaining Questions
Viet Nam has contributed research to the evolving evidence base for circulating tumor DNA testing.
A retrospective multicenter study by Nguyen Hoang and colleagues, published in JCO Oncology Advances in March 2025, examined the real-world use of a personalized tumor-informed ctDNA assay among patients with several types of solid tumors.
The analysis included 623 patients and 815 plasma samples collected in routine clinical practice between August 2022 and December 2023.
For 263 patients with early-stage cancer, clinical follow-up information was available to examine the prognostic value of ctDNA for recurrence.
The study reported findings supporting the feasibility of ctDNA testing and its potential to provide information about recurrence risk across several cancer types.
This evidence is relevant because Southeast Asian populations have been comparatively underrepresented in many molecular oncology studies.
However, the study was retrospective and involved a particular commercial assay and testing population. The available follow-up data covered only a subset of patients, and the research was supported by the assay developer.
These characteristics do not invalidate the findings, but they are important when considering how broadly the results can be applied.
The study should not be interpreted as demonstrating that ctDNA-guided treatment decisions improve survival across all cancers or that the assay's performance can be generalized to every laboratory in Viet Nam.
It also does not establish that the absence of detectable ctDNA can safely replace conventional follow-up.
Its contribution is to demonstrate the practical feasibility and potential prognostic value of ctDNA testing in a Vietnamese clinical setting.
For healthcare organizations, such evidence can inform implementation discussions, but clinical utility and suitability still need to be assessed according to the specific intended use.
Locally relevant research is valuable because it helps distinguish promising technical capabilities from applications whose clinical benefits have been demonstrated through appropriate evaluation.
Measuring the Reliability of ctDNA Services
Healthcare organizations may initially assess ctDNA services through the number of tests ordered, laboratory turnaround time or the proportion of reports identifying potentially actionable alterations.
These measures can describe activity, but they do not independently establish diagnostic reliability.
A high rate of detected variants may reflect the cancer types examined, disease stage, treatment history, assay coverage or patient selection rather than superior testing performance.
Similarly, a low rate of technical failure does not demonstrate that negative findings are being interpreted appropriately.
A more useful evaluation begins with test appropriateness.
The organization can examine whether requests include a documented clinical indication and whether the selected assay is suitable for the decision being considered.
Specimen quality provides another important area for assessment. Laboratories may review the proportion of specimens failing predefined acceptance criteria, the reasons for failure and whether appropriate corrective action was taken.
Reporting quality can be evaluated through the completeness of information concerning assay limitations, variant interpretation and circumstances that may require further assessment.
The handling of inconclusive and discordant findings is particularly important.
Healthcare organizations may review cases in which tissue-based confirmation or another investigation was clinically indicated and determine whether the issue was appropriately resolved.
The denominator should include cases in which further assessment was relevant and reasonably considered, rather than treating every negative ctDNA result as requiring another test.
Turnaround time should also be connected to clinical decision-making.
A rapid plasma report may offer limited benefit if an uninformative result leads to a prolonged delay before appropriate tissue testing is arranged.
For selected pathways, the interval between the initial molecular test request and the availability of information sufficient for the intended clinical decision may be more meaningful than laboratory turnaround time alone.
Discordant plasma and tissue findings also deserve structured review.
Such differences may arise from analytical limitations, tumor heterogeneity, differences between sampling times, treatment effects or non-tumor sources of circulating DNA.
Discordance does not automatically establish that either examination was performed incorrectly.
Quality improvement should focus on identifying recurring weaknesses in assay selection, specimen handling, interpretation, reporting and completion of appropriate follow-up.
The purpose of measurement is to determine whether patients receive molecular information that is sufficiently reliable and clinically relevant to support responsible decisions.
Professional Accountability and Multidisciplinary Review
CtDNA testing brings together several areas of professional expertise, including oncology, molecular pathology, laboratory medicine, bioinformatics and, in selected circumstances, clinical genetics.
These disciplines have related but distinct responsibilities.
The treating oncologist determines whether molecular testing is clinically appropriate and how the findings relate to the patient's condition and available treatment options.
The laboratory is responsible for the validation, performance and reporting of examinations within its authorized professional scope.
Molecular pathologists and appropriately qualified laboratory specialists contribute to interpreting alterations, understanding technical limitations and identifying potential sources of misleading findings.
Clinical genetics professionals may become involved when results raise a legitimate concern about inherited cancer susceptibility.
Healthcare organizations should establish how these responsibilities are coordinated.
A multidisciplinary molecular tumor board or equivalent professional review process may be valuable when findings are complex, discordant or likely to influence major treatment decisions.
However, multidisciplinary discussion does not replace the need for reliable laboratory procedures or clear individual accountability.
Oversight of external laboratories also matters.
When specimens are referred to domestic or international providers, the referring organization should understand the intended use of the assay, its quality arrangements, reporting limitations and procedures for obtaining technical clarification.
The use of a recognized commercial platform should not replace appropriate assessment of its capabilities.
Likewise, laboratory accreditation or certification should be evaluated according to its actual scope rather than assumed to cover every molecular assay offered.
These arrangements help ensure that ctDNA testing remains part of an accountable clinical service rather than an isolated commercial transaction.
Applying International Evidence in Viet Nam
The development of molecular oncology services creates opportunities for healthcare organizations in Viet Nam to strengthen personalized cancer care.
However, technological availability does not establish that every possible clinical application is appropriate.
Healthcare facilities differ in their molecular testing capabilities, access to specialized interpretation, financial resources and arrangements for obtaining tumor tissue or referring specimens.
Some examinations may be performed locally, while others depend on domestic reference laboratories or international service providers.
These differences can affect turnaround time, affordability, access to specialist advice and the feasibility of additional investigations.
International guidance provides an important foundation for addressing these challenges.
The 2026 ASCO guideline supports selecting ctDNA testing according to its intended clinical use and the evidence available for that use.
ESMO's recommendations clarify limitations of plasma-based genotyping and the need to consider tissue-based testing when results are uninformative.
The 2026 French consensus and BLOODPAC publications provide additional technical references for analytical validation, laboratory quality and reporting.
The IMvigor011 trial and subsequent FDA approval demonstrate how clinical utility can be established for a particular ctDNA-guided treatment pathway.
Nevertheless, these international developments do not automatically establish identical clinical, regulatory or reimbursement arrangements in Viet Nam.
The applicable Vietnamese legal framework includes the Law on Medical Examination and Treatment No. 15/2023/QH15 and Decree No. 96/2023/ND-CP.
Healthcare organizations must conduct professional and technical activities within the scope authorized under applicable licensing and regulatory arrangements.
Circular No. 23/2024/TT-BYT establishes the lists of medical examination and treatment techniques.
It was amended by Circular No. 25/2026/TT-BYT, issued on June 30, 2026.
Although Circular No. 25/2026/TT-BYT generally took effect on August 15, 2026, its Articles 2 and 3 took effect on July 1, 2026.
The Ministry of Health issued Consolidated Document No. 13/2026/VBHN-TT-BYT on July 30, 2026, reflecting the relevant amendments concerning the lists of medical examination and treatment techniques.
Under the amended transition arrangements, the technical list in Appendix 01 continues to apply through December 31, 2027, while Appendix 02 applies from January 1, 2028.
The consolidated document helps readers understand the amended provisions. It should not be treated as independently creating legal obligations beyond those established by the underlying regulatory instruments.
For ctDNA services, healthcare organizations should determine which professional and technical activities they are authorized to perform and assess applicable requirements concerning laboratory examinations, medical devices, specimen referral and the introduction of relevant techniques.
An FDA-approved companion diagnostic or treatment indication does not automatically have the same regulatory status in Viet Nam.
The requirements applicable to a particular assay, medical device or therapeutic product must therefore be determined under the relevant Vietnamese framework.
For laboratories, TCVN ISO 15189:2025 is identical to ISO 15189:2022 and provides a relevant framework for laboratory quality and competence.
It supports controlled procedures for examination validation, personnel competence, risk management, reporting and oversight of externally provided laboratory services.
However, publication of a national standard does not automatically mean that every medical laboratory in Viet Nam is legally required to obtain accreditation against it.
Requirements must be assessed according to applicable regulations, authorized activities and any relevant accreditation or contractual commitments.
Laboratory quality management arrangements should also consider Circular No. 01/2013/TT-BYT, as amended, including by Circular No. 25/2026/TT-BYT.
Protecting Sensitive Molecular and Genetic Information
CtDNA testing can generate sensitive health and genetic information.
Healthcare organizations therefore need to consider how specimens and data are collected, transferred, analyzed, stored, accessed and retained.
These responsibilities become particularly important when testing involves external laboratories, international service providers or cloud-based bioinformatic systems.
Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.
Organizations processing identifiable molecular or genetic information should assess the applicable requirements concerning lawful processing, confidentiality, authorized access, information security and disclosure or transfer of personal data.
Consent requirements, applicable exceptions and other legal conditions depend on the nature and purpose of the processing activity.
A patient's agreement to undergo molecular testing should not automatically be treated as unrestricted authorization for research use, international data sharing or disclosure of identifiable information beyond the purposes permitted by law.
Where overseas laboratories or technology providers are involved, healthcare organizations should understand what information is shared, who can access it and which cross-border data protection requirements apply.
Appropriate arrangements should also identify responsibilities for reporting, data security and communication when technical problems or clinically important questions arise.
Patient communication remains important throughout the process.
A person undergoing ctDNA testing should receive an understandable explanation of the examination's purpose and limitations, particularly when a negative result cannot exclude a relevant alteration or when additional tissue testing may be necessary.
Where findings raise the possibility of inherited genetic risk, the healthcare team should have an appropriate pathway for further professional evaluation and communication.
Access and affordability also deserve attention.
A costly molecular examination that cannot reasonably contribute to a clinical decision may impose financial burdens without corresponding benefit.
Conversely, patients may lose opportunities for appropriate treatment when clinically useful molecular testing is unavailable or substantially delayed.
The objective should be to support appropriate access to evidence-based molecular testing rather than maximize the number of examinations performed.
Making ctDNA Reliability Part of Routine Clinical Governance
Healthcare organizations can begin strengthening ctDNA reliability without establishing an entirely new governance structure.
A practical starting point is to review a defined group of recent cases and examine whether the test was appropriate, whether its limitations were understood and whether necessary further assessment was completed.
For example, a hospital may review patients with advanced cancer whose plasma molecular profiling did not identify actionable alterations.
The review could examine whether the assay covered the relevant biomarkers, whether suitable tumor tissue was available and whether tissue-based testing was considered when the plasma result did not adequately answer the clinical question.
A different review might examine cases involving detected variants that could have originated from clonal hematopoiesis.
The organization could assess whether appropriate molecular pathology expertise was available and whether clinically important uncertainty was addressed before treatment decisions were made.
For MRD testing, the focus should be whether the examination was supported by evidence for its intended use and whether the subsequent clinical response was justified.
A positive molecular finding should not automatically trigger additional treatment or intensified surveillance without an appropriate evidence-supported pathway.
These reviews may reveal different opportunities for improvement.
Some problems may require clearer explanations of assay limitations. Others may involve better access to molecular pathology consultation, improved laboratory reporting or more reliable procedures for obtaining existing tumor tissue.
Where testing is performed externally, improvements may involve communication with referral laboratories or clarification of responsibility for arranging additional investigations.
Changes should be evaluated through subsequent cases rather than assumed to be effective simply because a policy has been updated or training has been completed.
A reliable diagnostic service should be able to recognize when the initial molecular result is insufficient and ensure that the unresolved clinical question receives appropriate attention.
Strengthening ctDNA Testing as Part of Diagnostic Excellence
Circulating tumor DNA testing represents an important development in precision oncology.
It can provide clinically useful molecular information when tissue testing is difficult, support treatment selection in defined circumstances and contribute to emerging approaches for assessing molecular residual disease.
The evidence available in 2026 demonstrates both the potential and the limitations of these technologies.
The ASCO guideline emphasizes appropriate use and further assessment when plasma findings are negative, inconclusive or inconsistent with clinical circumstances.
ESMO's recommendations reinforce the importance of understanding assay limitations and retaining tissue-based testing when necessary.
Recent technical consensus work highlights the continuing need for reliable specimen handling, molecular analysis, bioinformatics, validation and reporting.
At the same time, the IMvigor011 trial and the FDA approval in May 2026 demonstrate that ctDNA-guided care can provide measurable benefit when the assay, patient population and treatment decision are supported by appropriate evidence.
These developments should encourage careful implementation rather than unrestricted expansion.
For healthcare organizations in Viet Nam, diagnostic reliability depends on understanding not only what a molecular test can detect, but also what it cannot establish.
A negative plasma result may leave a clinically important alteration unidentified. A positive result may require consideration of its biological origin. A molecular residual disease signal may provide prognostic information without necessarily justifying intervention outside an evidence-supported setting.
The value of ctDNA testing should therefore not be measured by the sophistication of the technology, the number of detected variants or the speed with which a report is produced.
Diagnostic excellence in ctDNA testing depends on selecting an appropriate examination for a meaningful clinical question, interpreting findings within their validated limitations and establishing a dependable pathway for resolving uncertainty before consequential clinical decisions are made.
Selected References and Regulatory Sources
Lockwood CM, Messersmith HJ, Kim AS, et al. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline. JCO Oncology Practice. 2026;22(9):1468–1489. Published online June 18, 2026. DOI: 10.1200/OP-26-00311.
Pascual J, Attard G, Bidard FC, et al. ESMO Recommendations on the Use of Circulating Tumour DNA Assays for Patients With Cancer: A Report From the ESMO Precision Medicine Working Group. Annals of Oncology. 2022;33(8):750–768. DOI: 10.1016/j.annonc.2022.05.520.
Harlé A, Payen L, Lespagnol A, et al. Technical Recommendations From a Large-Scale French Delphi Consensus: A Step Toward European Harmonization of ctDNA Analysis. European Journal of Cancer. 2026;242:116791. Published online May 12, 2026. DOI: 10.1016/j.ejca.2026.116791.
Harlé A, Payen L, Lespagnol A, et al. Recommandations nationales du GFCO sur l'analyse de l'ADN tumoral circulant par biopsie liquide pour le diagnostic et la progression du cancer: bonnes pratiques pré-analytiques, analytiques et post-analytiques. Bulletin du Cancer. 2026;113(10):1163–1174. DOI: 10.1016/j.bulcan.2026.05.008.
Baden J, Lin CHJ, Anfora AT, et al. Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation. JCO Precision Oncology. 2026;10. Published January 14, 2026. DOI: 10.1200/PO-25-00267.
Silvestro A, Baden J, Billings K, et al. Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0. JCO Precision Oncology. 2026;10. Published May 11, 2026. DOI: 10.1200/PO-25-01243.
Powles T, Kann AG, Castellano D, et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. New England Journal of Medicine. 2025;393(24):2395–2408. Published online October 20, 2025. DOI: 10.1056/NEJMoa2511885.
U.S. Food and Drug Administration. FDA Approves Atezolizumab for Adjuvant Treatment of Muscle-Invasive Bladder Cancer in Patients With Molecular Residual Disease. May 15, 2026.
U.S. Food and Drug Administration. Signatera CDx, Premarket Approval P260004. Approved May 15, 2026.
Nguyen Hoang VA, Nguyen N, Le DN, et al. Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors. JCO Oncology Advances. 2025;2. Published online March 7, 2025. DOI: 10.1200/OA-24-00084.
International Organization for Standardization. ISO 15189:2022: Medical Laboratories — Requirements for Quality and Competence.
Viet Nam National Standard. TCVN ISO 15189:2025: Medical Laboratories — Requirements for Quality and Competence. Identical to ISO 15189:2022, replacing TCVN ISO 15189:2014.
National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. Effective January 1, 2024, as amended.
Government of Viet Nam. Decree No. 96/2023/ND-CP, Detailing Certain Articles of the Law on Medical Examination and Treatment. December 30, 2023.
Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, Guiding the Implementation of Laboratory Quality Management at Medical Examination and Treatment Facilities. January 11, 2013, as amended.
Ministry of Health of Viet Nam. Circular No. 23/2024/TT-BYT, Promulgating the List of Medical Examination and Treatment Techniques. October 18, 2024, as amended.
Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, Amending and Supplementing Certain Provisions of Circular No. 01/2013/TT-BYT, Circular No. 32/2023/TT-BYT, Circular No. 23/2024/TT-BYT and Circular No. 42/2025/TT-BYT. June 30, 2026. Articles 2 and 3 effective July 1, 2026; general effective date August 15, 2026.
Ministry of Health of Viet Nam. Consolidated Document No. 13/2026/VBHN-TT-BYT, Consolidating the Regulations on the List of Medical Examination and Treatment Techniques. July 30, 2026.
National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.
Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Measures for Implementing the Law on Personal Data Protection. Effective January 1, 2026.
Professional Scope and Disclaimer
This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement and quality improvement.
The content is intended for general professional education and discussion. It does not constitute patient-specific medical advice, a cancer diagnosis, a molecular testing or treatment protocol, an individualized recommendation concerning ctDNA testing, tissue-based confirmation, molecular residual disease management, surveillance or cancer treatment, a determination of professional or technical error, an accreditation assessment or legal advice.
The discussion focuses primarily on ctDNA testing in oncology, particularly tumor molecular profiling and selected molecular residual disease applications. Other liquid biopsy technologies, hereditary cancer testing, multicancer early-detection screening and specialized molecular applications may require additional evidence and professional guidance.
References to ASCO, ESMO, BLOODPAC, ISO, FDA approvals and other international professional or regulatory sources do not imply endorsement of this publication by the organizations concerned. International recommendations and foreign regulatory approvals are not automatically mandatory or applicable under Vietnamese law.
The applicability of professional standards, laboratory quality requirements, medical device regulations and Vietnamese laws depends on the healthcare organization's authorized activities, relevant regulations and applicable accreditation or contractual commitments.
Decisions concerning ctDNA test selection, molecular interpretation, confirmatory investigations, clinical assessment and cancer management must be undertaken by appropriately qualified and authorized healthcare professionals in accordance with applicable Vietnamese law, relevant professional standards, validated laboratory procedures and the patient's clinical circumstances.
Diagnostic Excellence Vietnam does not provide molecular testing, individualized cancer diagnosis, treatment or certification of molecular laboratory services through this educational publication.
